Title: Comparison of the efficacy and safety between rivaroxaban and dabigatran in the
treatment of acute portal vein thrombosis in cirrhosis
Version: 5 Date: 23 Jul 2023
Reviewer's report:
As the author mentioned that all patients underwent esophagoscopy prior anticoagulation, Please
showed the details of the gastroesophageal varices. Please add the severity of esophageal varices.
How many patients had prior banding for prophylaxis of variceal bleeding? How many patients
had a history of variceal bleeding and underwent endoscopic treatment?
As for the duration of anticoagulant therapy, it is obviously non-normally distribution. Please
show the median (IQR) rather than mean±SD.
Which imaging was used to evaluate the recanalization of PVT? Please show how many patients
had MRI, CTA or ultrasound?
Figure 1 (Study flow chart) should be showed according to the STROBE guideline.
The latest guideline should be BAVENO VII, please re-checked.
Table 2 and Table 3 are meaningless. In addition, some variables had interaction with each other.
Title: Comparison of the efficacy and safety between rivaroxaban and dabigatran in the
treatment of acute portal vein thrombosis in cirrhosis
Version: 5 Date: 23 Jul 2023
Reviewer's report:
As the author mentioned that all patients underwent esophagoscopy prior anticoagulation, Please
showed the details of the gastroesophageal varices. Please add the severity of esophageal varices.
How many patients had prior banding for prophylaxis of variceal bleeding? How many patients
had a history of variceal bleeding and underwent endoscopic treatment?
As for the duration of anticoagulant therapy, it is obviously non-normally distribution. Please
show the median (IQR) rather than mean±SD.
Which imaging was used to evaluate the recanalization of PVT? Please show how many patients
had MRI, CTA or ultrasound?
Figure 1 (Study flow chart) should be showed according to the STROBE guideline.
The latest guideline should be BAVENO VII, please re-checked.
Table 2 and Table 3 are meaningless. In addition, some variables had interaction with each other.
Please review this paper.
user
Title: Comparison of the efficacy and safety between rivaroxaban and dabigatran in the
treatment of acute portal vein thrombosis in cirrhosis
Version: 5 Date: 23 Jul 2023
Reviewer's report:
As the author mentioned that all patients underwent esophagoscopy prior anticoagulation, Please
showed the details of the gastroesophageal varices. Please add the severity of esophageal varices.
How many patients had prior banding for prophylaxis of variceal bleeding? How many patients
had a history of variceal bleeding and underwent endoscopic treatment?
As for the duration of anticoagulant therapy, it is obviously non-normally distribution. Please
show the median (IQR) rather than mean±SD.
Which imaging was used to evaluate the recanalization of PVT? Please show how many patients
had MRI, CTA or ultrasound?
Figure 1 (Study flow chart) should be showed according to the STROBE guideline.
The latest guideline should be BAVENO VII, please re-checked.
Table 2 and Table 3 are meaningless. In addition, some variables had interaction with each other.
assistant